PLX logo

PROTALIX BIOTHERAPEUTICS INC

PLXNYSE AMERICAN
🏆 #3661 by market capUS Equity
$725.91▼ $51.90 (−7.15%)
Simulated price
🔔
Track PLX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.2%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$219M
Small Cap
📈Revenue Growth (YoY)
-1.2%
Declining
📊Gross Margin
69.2%
High
💵FCF Margin
9.5%
Moderate
⚖️P/S Ratio
2.7x
Cheap
Otter Score
80
Good
No chart data available for PLX.

Trading Snapshot

Day Range
$717.20 – $732.61
52-Week Range
$1.60 – $3.19
Volume
$3.34B
Avg Volume
$2.44B
Shares Outstanding
80.6M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$53M
Last Q Revenue
$20M
P/E Ratio
11.3
P/S Ratio
2.7x
EPS (TTM)
$0.24
Dividend Yield
0.00%
Dilution (1yr)
−3.1%

Why Investors Own PLX

  • ✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 53% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLX logo

PROTALIX BIOTHERAPEUTICS INC

PLX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$53M▼ −1.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
47.8%▼ −12.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▼ −240.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14M▼ −284.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
78.5M▼ −3.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▼ −$8M YoY
StockOtter · stockotter.space

About PROTALIX BIOTHERAPEUTICS INC

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$707.61
▼ −2.5% Downside
High Target$787.20
Low Target$652.59
Based on 25 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

PROTALIX BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift PLX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

PROTALIX BIOTHERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.